 Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority IIA selected the Companys planned COVID-19 and sepsis clinical programs to receive, in the aggregate, a non-dilutive grant of approximately 1.5 million for the period through the first quarter of 2021. To date, Enlivex has received a total of approximately 4.31 million in grants from the IIA for its historical clinical trials and development. The IIA is an independent, publicly funded agency charged with fostering the development of industrial RD; within the State of Israel. 